Please be aware that all information shared here at Canada Pharmacy has been medically reviewed and fact-checked for accuracy. These verifications are made by board-certified medical professionals who have the authority required to state that information related to medical conditions, symptoms, procedures and tests, and standard treatment protocols is valid and truthful. This is based on current guidelines and consensuses shared amongst medical professionals, and in representation of the latest research.
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Also Known as Brilique
Brilinta (ticagrelor) is available by prescription only to decrease the risk of the following conditions:
Brilinta is available in 60 mg and 90 mg oral tablets.
Follow your doctor's instructions on how to take Brilinta. Tell your doctor or pharmacist about any questions or concerns you may have.
Brilinta dosing depends on the condition being treated and is recommended to be taken with aspirin. Consult with your doctor about how much Brilinta and aspirin is right for you.
The active ingredient in Brilinta is ticagrelor.
Inactive ingredients in the 60 mg tablets include mannitol, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol 400, ferric oxide black, and ferric oxide red.
Inactive ingredients in the 90 mg tablets include mannitol, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, talc, polyethylene glycol 400, and ferric oxide yellow.
Patients who have had bleeding in the brain, active bleeding, or an allergy to ticagrelor or to any of its excipients should not take the medication.
Brilinta has an FDA Boxed Warning regarding the risk of significant and potentially fatal bleeding. Brilinta should not be administered to patients with active pathological bleeding or a history of bleeding in the brain. In addition, Brilinta should not be administered to patients undergoing urgent coronary artery bypass graft surgery (CABG). If bleeding occurs, it is recommended to be managed without stopping Brilinta, if possible; stopping Brilinta can increase the risk of cardiovascular events.
Brilinta also has an FDA Boxed Warning against taking 100 mg or more of aspirin with Brilinta, as doing so can decrease Brilinta's effects.
Common Brilinta medication side effects include bleeding and shortness of breath; however, these are not all the side effects that can occur. Contact your doctor right away if you have side effects that are bothersome or persistent.
Brilinta (ticagrelor). Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.